Published by
Ministry of Health, Labour and Welfare

Translated by
Pharmaceuticals and Medical Devices Agency

Revision of Precautions

Concentrated human blood platelet (non-irradiated preparations)

Synthetic blood (non-irradiated preparations)

Washed human red blood cell (non-irradiated preparations)

December 17, 2021

Therapeutic category

Human blood preparations

Non-proprietary name

Concentrated human blood platelet, synthetic blood, washed human red blood cells

Safety measure

Precautions should be revised in the package insert.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revision in line with the Instructions for Package Inserts of Biological Products, PMSB/SD Notification No. 004 by the Director of Safety Division, Pharmaceutical and Medical Safety Bureau, MHLW, dated May 20, 2003 (Old instructions): Revised language is underlined.

Current	Revision
Warnings Cases of pyrexia and erythema that developed 1 to 2 weeks after transfusion of this drug, followed by death from graft versus host disease (GVHD) accompanied by diarrhoea, hepatic impairment, granulocytopenia, etc. have been rarely reported. When blood transfusion is performed in a patient considered to be at a high risk of GVHD, radiation at 15 to 50 Gy should be applied to this drug in advance.	Warnings Cases of pyrexia and erythema that developed 1 to 2 weeks after transfusion of this drug, followed by death from graft versus host disease (GVHD) accompanied by diarrhoea, hepatic impairment, granulocytopenia, etc. have been rarely reported. Radiation at 15 to 50 Gy should be applied to this drug prior to transfusion.
Precautions Concerning Dosage and Administration (N/A)	Precautions Concerning Dosage and Administration Irradiation: Radiation at 15 to 50 Gy should be applied to this drug prior to transfusion.
Adverse Reactions and Infections Clinically Significant Adverse Reactions and Infections GVHD: Cases of pyrexia and erythema that developed 1 to 2 weeks after transfusion of this drug, followed by death from GVHD accompanied by diarrhoea, hepatic impairment, granulocytopenia,	Adverse Reactions and Infections Clinically Significant Adverse Reactions and Infections GVHD: Cases of pyrexia and erythema that developed 1 to 2 weeks after transfusion of this drug, followed by death from GVHD accompanied by diarrhoea, hepatic impairment, granulocytopenia,

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

etc. have been reported. When blood transfusion is performed in a patient considered to be at a high risk of GVHD, radiation at 15 to 50 Gy should be applied to this drug in advance.	etc. have been reported.

N/A: Not Applicable. No corresponding language is included in the current package insert.